SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387161005> ?p ?o ?g. }

Showing items 1 to 65 of 65 with 100 items per page.

W4387161005 abstract "Abstract Aims Glioblastoma (GBM) is the highest-grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15–18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence; and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep screening strategy to identify repurposed candidate drugs against therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Main methods Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we further selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal, and by in silico molecular docking against each individual target using FDA approved drugs library from DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The effect of these final shortlisted compounds on a panel of GBM cell lines was examined and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and IC50 values obtained from GDSC portal. Key findings We identified RPA3, PSMA2, PSMC2, BLVRA and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458, linifanib, drospirenone, eltrombopag, nilotinib and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Significance Through this work we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes." @default.
W4387161005 created "2023-09-30" @default.
W4387161005 creator A5034116241 @default.
W4387161005 creator A5078786812 @default.
W4387161005 creator A5086988518 @default.
W4387161005 date "2023-09-29" @default.
W4387161005 modified "2023-09-30" @default.
W4387161005 title "A multistep in silico approach identifies potential glioblastoma drug candidates via inclusive molecular targeting of glioblastoma stem cells" @default.
W4387161005 doi "https://doi.org/10.21203/rs.3.rs-3358531/v1" @default.
W4387161005 hasPublicationYear "2023" @default.
W4387161005 type Work @default.
W4387161005 citedByCount "0" @default.
W4387161005 crossrefType "posted-content" @default.
W4387161005 hasAuthorship W4387161005A5034116241 @default.
W4387161005 hasAuthorship W4387161005A5078786812 @default.
W4387161005 hasAuthorship W4387161005A5086988518 @default.
W4387161005 hasBestOaLocation W43871610051 @default.
W4387161005 hasConcept C104317684 @default.
W4387161005 hasConcept C143998085 @default.
W4387161005 hasConcept C155261790 @default.
W4387161005 hasConcept C2775905019 @default.
W4387161005 hasConcept C2776194525 @default.
W4387161005 hasConcept C2778227246 @default.
W4387161005 hasConcept C2780035454 @default.
W4387161005 hasConcept C28328180 @default.
W4387161005 hasConcept C502942594 @default.
W4387161005 hasConcept C54355233 @default.
W4387161005 hasConcept C55427017 @default.
W4387161005 hasConcept C60644358 @default.
W4387161005 hasConcept C70721500 @default.
W4387161005 hasConcept C71924100 @default.
W4387161005 hasConcept C86803240 @default.
W4387161005 hasConcept C98274493 @default.
W4387161005 hasConceptScore W4387161005C104317684 @default.
W4387161005 hasConceptScore W4387161005C143998085 @default.
W4387161005 hasConceptScore W4387161005C155261790 @default.
W4387161005 hasConceptScore W4387161005C2775905019 @default.
W4387161005 hasConceptScore W4387161005C2776194525 @default.
W4387161005 hasConceptScore W4387161005C2778227246 @default.
W4387161005 hasConceptScore W4387161005C2780035454 @default.
W4387161005 hasConceptScore W4387161005C28328180 @default.
W4387161005 hasConceptScore W4387161005C502942594 @default.
W4387161005 hasConceptScore W4387161005C54355233 @default.
W4387161005 hasConceptScore W4387161005C55427017 @default.
W4387161005 hasConceptScore W4387161005C60644358 @default.
W4387161005 hasConceptScore W4387161005C70721500 @default.
W4387161005 hasConceptScore W4387161005C71924100 @default.
W4387161005 hasConceptScore W4387161005C86803240 @default.
W4387161005 hasConceptScore W4387161005C98274493 @default.
W4387161005 hasLocation W43871610051 @default.
W4387161005 hasOpenAccess W4387161005 @default.
W4387161005 hasPrimaryLocation W43871610051 @default.
W4387161005 hasRelatedWork W1499689199 @default.
W4387161005 hasRelatedWork W1870587587 @default.
W4387161005 hasRelatedWork W1976203623 @default.
W4387161005 hasRelatedWork W2074028522 @default.
W4387161005 hasRelatedWork W2083947856 @default.
W4387161005 hasRelatedWork W2086711430 @default.
W4387161005 hasRelatedWork W2411731991 @default.
W4387161005 hasRelatedWork W2482736996 @default.
W4387161005 hasRelatedWork W7626416 @default.
W4387161005 hasRelatedWork W4210971019 @default.
W4387161005 isParatext "false" @default.
W4387161005 isRetracted "false" @default.
W4387161005 workType "article" @default.